Lancer K Brown

age ~45

from Henderson, NV

Get Report

Also known as:

Lancer Melissa Brown
Kay Brown Lancer
Brown Lancer

Connected to:

Lancer Brown Phones & Addresses

Henderson, NV
10765 Misty Meadows Dr, Reno, NV 89521 • 702 274-5855
Sparks, NV
1375 Allen St, Fallon, NV 89406 • 775 423-8557
Fernley, NV
Humboldt, NV
Washoe, NV

Resumes

Chief Scientific Officer

view source

Location:

250 south Rock Blvd, Reno, NV 89502

Industry:

Biotechnology

Work:

University of Nevada Reno Jan 2001 - May 2002
Lab Technician
Sierra Sciences Jan 2001 - May 2002
Chief Scientific Officer

Education:

University of Nevada, Reno 1997 - 2003
Master of Science, Masters, Bachelors, Bachelor of Science, Biotechnology Churchill County High School

Skills:

Biochemistry
Dna Extraction
Pcr
Cell Culture
Molecular Biology
Dna
Elisa
Gel Electrophoresis
Polymerase Chain Reaction
Rna Isolation
Rnai
Aav
Lentivirus
Baculovirus

Languages:

English

Senior Molecular Biologist - Heligenics

view source

Location:

Reno, NV

Work:

Senior Molecular Biologist - Heligenics

Us Patents

Assays For Tert Promoter Modulatory Agents
view source
US Patent:

20080166711, Jul 10, 2008
Filed:

Mar 12, 2007
Appl. No.:

11/717572
Inventors:

William H. Andrews - Reno NV, US
Laura A. Briggs - Reno NV, US
Christopher A. Foster - Carmichael CA, US
Mieczyslaw A. Piatyszek - Morgan Hill CA, US
Lancer K. Brown - Sparks NV, US
International Classification:

C12Q 1/68
US Classification:

435 6
Abstract:

Methods and compositions for assaying an agent for TERT promoter modulatory activity are provided. In the subject methods, an agent is contacted with a cell comprising a mutant telomerase structural RNA component (TR) that results in a detectable phenotype in the presence of telomerase reverse transcriptase (TERT). Also provided are compositions, systems and kits thereof, as well as devices, that find use in practicing the subject methods. The subject invention finds use in assaying agents for TERT promoter modulatory activity, such as in a high throughput format.

Methods And Compositions For Modulating Telomerase Reverse Transcriptase (Tert) Expression
view source
US Patent:

20080213812, Sep 4, 2008
Filed:

Jan 18, 2008
Appl. No.:

12/009623
Inventors:

William H. Andrews - Reno NV, US
Laura Briggs - Reno NV, US
Christopher Foster - Reno NV, US
Hamid Mohammadpour - Reno NV, US
Stephanie Fraser - Sparks NV, US
David Monda - Sparks NV, US
Lancer Brown - Sparks NV, US
Frederick M. Hahn - San Rafael CA, US
Ronald Pruzan - Palo Alto CA, US
David Schooley - Reno NV, US
Jason March - Reno NV, US
International Classification:

C12Q 1/48
C12N 5/06
US Classification:

435 15, 435375
Abstract:

Methods and compositions are provided for modulating, e.g., increasing or decreasing, the expression of telomerase reverse transcriptase (TERT). In the subject methods, the binding interaction of the TERT Site C repressor site with a Site C repressor protein complex made up of one or more proteins is modulated to achieve the desired change in TERT expression. A feature of the subject invention is that the target Site C repressor protein complex includes an LSF protein. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like.

Methods And Compositions For Modulating Telomerase Reverse Transcriptase (Tert) Expression
view source
US Patent:

20080268467, Oct 30, 2008
Filed:

Jan 18, 2008
Appl. No.:

12/009638
Inventors:

William H. Andrews - Reno NV, US
Laura Briggs - Reno NV, US
Christopher A. Foster - Carmichael CA, US
Hamid Mohammadpour - Reno NV, US
Stephanie Fraser - Sparks NV, US
Lancer Brown - Sparks NV, US
Frederick M. Hahn - San Rafael CA, US
International Classification:

G01N 33/53
C07K 1/00
C12N 5/06
C12N 9/00
US Classification:

435 72, 530402, 435375, 435183, 435 78
Abstract:

Methods and compositions are provided for modulating, e.g., increasing or decreasing, the expression of telomerase reverse transcriptase (TERT). In the subject methods, the binding interaction of the TERT Site C repressor site with a Site C repressor protein complex made up of one or more proteins is modulated to achieve the desired change in TERT expression. A feature of the subject invention is that the target Site C repressor protein complex includes a MRG15 protein. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like.

Compounds That Increase Telomerase Reverse Transcriptase (Tert) Expression And Methods For Using The Same
view source
US Patent:

20090143451, Jun 4, 2009
Filed:

Nov 13, 2008
Appl. No.:

12/270552
Inventors:

William H. Andrews - Reno NV, US
Laura A. Briggs - Reno NV, US
Christopher A. Foster - Carmichael CA, US
Lancer K. Brown - Sparks NV, US
Mieczyslaw A. Piatyszek - Morgan Hill CA, US
Federico C.A. Gaeta - Mountain View CA, US
Munirathnam Chaguturu - Lawrence KS, US
Jian Zhang - Fremont CA, US
Tom Kerley - Gardnerville NV, US
International Classification:

A61K 31/422
C12N 5/02
C12Q 1/02
US Classification:

514378, 435375, 435 29
Abstract:

Compounds, and methods of using the same, are provided which increase the expression of telomerase reverse transcriptase (TERT) in a cell. These compounds and methods find use in a variety of applications in which increased expression of telomerase is desired, including immortalization of cell lines and treating conditions in a subject characterized by cellular senescence.

Assays For Tert Promoter Modulatory Agents Using A Telomerase Structural Rna Component
view source
US Patent:

7226744, Jun 5, 2007
Filed:

Mar 21, 2005
Appl. No.:

11/085872
Inventors:

William H. Andrews - Reno NV, US
Laura Briggs - Reno NV, US
Lancer K. Brown - Sparks NV, US
Christopher A. Foster - Reno NV, US
Mieczyslaw A. Piatyszek - Morgan Hill CA, US
Assignee:

Sierra Sciences, Inc. - Reno NV
International Classification:

C12Q 1/68
US Classification:

435 6, 435455
Abstract:

Methods and compositions for assaying an agent for TERT promoter modulatory activity are provided. In the subject methods, an agent is contacted with a cell comprising a mutant telomerase structural RNA component (TR) that results in a detectable phenotype in the presence of telomerase reverse transcriptase (TERT). Also provided are compositions, systems and kits thereof, as well as devices, that find use in practicing the subject methods. The subject invention finds use in assaying agents for TERT promoter modulatory activity, such as in a high throughput format.

Enhancing Health In Mammals Using Telomerase Reverse Transcriptase Gene Therapy
view source
US Patent:

20210361751, Nov 25, 2021
Filed:

May 26, 2021
Appl. No.:

17/331178
Inventors:

- Reno NV, US
Lancer K. Brown - Sparks NV, US
Hamid Mohammadpour - Reno NV, US
Laura A. Briggs - Reno NV, US
International Classification:

A61K 38/45
C12N 9/12
C12N 7/00
A61K 48/00
Abstract:

Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nuclcic acid vectors and kits, etc., that find use in methods of the invention.

Enhancing Health In Mammals Using Telomerase Reverse Transcriptase Gene Therapy
view source
US Patent:

20200306348, Oct 1, 2020
Filed:

Feb 27, 2020
Appl. No.:

16/803006
Inventors:

- Reno NV, US
Lancer K. Brown - Sparks NV, US
Hamid Mohammadpour - Reno NV, US
Laura A. Briggs - Reno NV, US
International Classification:

A61K 38/45
C12N 9/12
C12N 7/00
A61K 48/00
Abstract:

Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.

Enhancing Health In Mammals Using Telomerase Reverse Transcriptase Gene Therapy
view source
US Patent:

20180344816, Dec 6, 2018
Filed:

May 31, 2018
Appl. No.:

15/994421
Inventors:

- Reno NV, US
Lancer K. Brown - Sparks NV, US
Hamid Mohammadpour - Reno NV, US
Laura A. Briggs - Reno NV, US
International Classification:

A61K 38/45
A61K 48/00
C12N 9/12
C12N 7/00
Abstract:

Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.